These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Choice of biologics in asthma endotypes. Wangberg H; Woessner K Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486 [TBL] [Abstract][Full Text] [Related]
3. Asthma Phenotypes as a Guide for Current and Future Biologic Therapies. Hamilton D; Lehman H Clin Rev Allergy Immunol; 2020 Oct; 59(2):160-174. PubMed ID: 31359247 [TBL] [Abstract][Full Text] [Related]
4. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers. Santus P; Saad M; Damiani G; Patella V; Radovanovic D Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886 [TBL] [Abstract][Full Text] [Related]
5. Use of biomarkers to identify phenotypes and endotypes of severeasthma. Carr TF; Kraft M Ann Allergy Asthma Immunol; 2018 Oct; 121(4):414-420. PubMed ID: 30059792 [TBL] [Abstract][Full Text] [Related]
6. Biologic Therapy and Novel Molecular Targets of Severe Asthma. Pepper AN; Renz H; Casale TB; Garn H J Allergy Clin Immunol Pract; 2017; 5(4):909-916. PubMed ID: 28689841 [TBL] [Abstract][Full Text] [Related]
7. Emerging care management strategies for severe asthma: integrating biologic therapy. Spjut R Am J Manag Care; 2022 Sep; 28(11 Suppl):S203-S209. PubMed ID: 36648385 [TBL] [Abstract][Full Text] [Related]
8. Biological treatments for severe asthma. Assaf SM; Hanania NA Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594 [TBL] [Abstract][Full Text] [Related]
9. Applying personalized medicine to adult severe asthma. Tiotiu A Allergy Asthma Proc; 2021 Jan; 42(1):e8-e16. PubMed ID: 33404396 [No Abstract] [Full Text] [Related]
11. Asthma phenotypes and endotypes: a personalized approach to treatment. Skloot GS Curr Opin Pulm Med; 2016 Jan; 22(1):3-9. PubMed ID: 26574717 [TBL] [Abstract][Full Text] [Related]
12. Asthma Phenotypes and Endotypes: Implications for Personalised Therapy. Dean K; Niven R BioDrugs; 2017 Oct; 31(5):393-408. PubMed ID: 28879503 [TBL] [Abstract][Full Text] [Related]
13. Biologics and biomarkers for asthma, urticaria, and nasal polyposis. Casale TB J Allergy Clin Immunol; 2017 May; 139(5):1411-1421. PubMed ID: 28477720 [TBL] [Abstract][Full Text] [Related]
14. Personalized Medicine in Severe Asthma: From Biomarkers to Biologics. Chen CY; Wu KH; Guo BC; Lin WY; Chang YJ; Wei CW; Lin MJ; Wu HP Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203353 [TBL] [Abstract][Full Text] [Related]
15. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Parulekar AD; Diamant Z; Hanania NA Curr Opin Pulm Med; 2017 Jan; 23(1):3-11. PubMed ID: 27820746 [TBL] [Abstract][Full Text] [Related]
16. How to compare the efficacy of biologic agents in asthma. Viswanathan RK; Busse WW Ann Allergy Asthma Immunol; 2020 Aug; 125(2):137-149. PubMed ID: 32387169 [TBL] [Abstract][Full Text] [Related]
17. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Rogers L; Jesenak M; Bjermer L; Hanania NA; Seys SF; Diamant Z Respir Med; 2023 Nov; 218():107414. PubMed ID: 37776915 [TBL] [Abstract][Full Text] [Related]
18. Evolving phenotypes to endotypes: is precision medicine achievable in asthma? Bagnasco D; Passalacqua G; Caminati M; Heffler E; Menzella F; De Ferrari L; Riccio AM; Folli C; Canonica GW Expert Rev Respir Med; 2020 Feb; 14(2):163-172. PubMed ID: 31899999 [No Abstract] [Full Text] [Related]
19. Characterization of asthma endotypes: implications for therapy. Stokes JR; Casale TB Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539 [TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine. Schoettler N; Strek ME Chest; 2020 Mar; 157(3):516-528. PubMed ID: 31678077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]